SRRA · Sierra Oncology, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $17.55M | - | $21.62M | $14.15M | $13.95M | - | $10.43M | $10.19M | $11.59M | - |
| SG&A | $10.33M | - | $6.99M | $6.42M | $5.87M | - | $4.11M | $6.26M | $4.54M | - |
| Total Operating Expenses | $27.88M | - | $28.60M | $20.57M | $19.82M | - | $14.54M | $16.45M | $16.14M | - |
| D&A | $92.0K | - | $11.0K | $11.0K | $47.0K | - | $34.0K | $15.00M | $55.0K | - |
| Operating Income | ($27.88M) | - | ($28.60M) | ($20.57M) | ($19.82M) | - | ($14.44M) | ($16.45M) | ($16.14M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | ($14.0K) | - | $47.0K | $9.0K | $68.0K | - | $39.0K | ($11.0K) | $78.0K | - |
| Net Income | ($27.93M) | - | ($28.65M) | ($20.63M) | ($19.91M) | - | ($14.51M) | ($16.46M) | ($31.91M) | - |
| EPS - Basic | - | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $274.01M | $104.75M | $97.07M | $90.69M | $107.66M | $104.06M | $109.01M | $123.23M | $133.53M | $147.53M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.80M | $2.16M | $846.0K | $1.55M | $2.52M | $2.21M | $1.54M | $1.98M | $1.36M | $1.02M |
| Current Assets | $278.20M | $107.39M | $102.72M | $92.67M | $109.67M | $106.47M | $111.97M | $124.63M | $135.47M | $149.90M |
| Total Assets | $280.00M | $109.37M | $104.23M | $94.38M | $110.56M | $107.49M | $113.04M | $125.89M | $136.79M | $151.33M |
| Current Liabilities | $13.08M | $12.88M | $8.63M | $9.46M | $8.89M | $9.35M | $7.47M | $8.98M | $7.00M | $64.61M |
| Long-term Debt | $4.86M | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $18.38M | $13.37M | $9.17M | $10.11M | $9.01M | $9.53M | $7.68M | $9.24M | $7.29M | $64.98M |
| Stockholders' Equity | $261.62M | $96.00M | $95.06M | $84.27M | $101.56M | $97.96M | $105.36M | $116.65M | $129.50M | $86.34M |
| Retained Earnings | ($969.18M) | ($941.25M) | ($915.78M) | ($887.13M) | ($866.50M) | ($846.59M) | ($828.57M) | ($814.06M) | ($797.60M) | ($765.69M) |
Cash Flow
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($25.74M) | - | - | - | ($16.96M) | - | - | - | ($13.95M) | - |
| Investing Cash Flow | ($62.0K) | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $195.06M | - | - | - | $20.58M | - | - | - | - | - |
| CapEx | $62.0K | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | ($25.80M) | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.92 | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -10.0% | - | -27.5% | -21.9% | -18.0% | - | -12.8% | -13.1% | -23.3% | - |
| Return on equity | -10.7% | - | -30.1% | -24.5% | -19.6% | - | -13.8% | -14.1% | -24.6% | - |
| Return on invested capital | -8.3% | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 21.27 | 8.34 | 11.91 | 9.80 | 12.34 | 11.38 | 15.00 | 13.88 | 19.36 | 2.32 |
| Quick ratio | 21.27 | 8.34 | 11.91 | 9.80 | 12.34 | 11.38 | 15.00 | 13.88 | 19.36 | 2.32 |
| Cash ratio | 20.95 | 8.13 | 11.25 | 9.59 | 12.12 | 11.13 | 14.60 | 13.72 | 19.08 | 2.28 |
| Leverage | ||||||||||
| Debt / Equity | 0.02 | - | - | - | - | - | - | - | - | - |
| Debt / Assets | 0.02 | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.07 | 1.14 | 1.10 | 1.12 | 1.09 | 1.10 | 1.07 | 1.08 | 1.06 | 1.75 |
| Liabilities / Assets | 0.07 | 0.12 | 0.09 | 0.11 | 0.08 | 0.09 | 0.07 | 0.07 | 0.05 | 0.43 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -40.7% | - | -98.0% | -25.1% | -22.8% | - | -8.9% | -8.2% | -19.5% | - |
| Net income growth (YoY) | -40.2% | - | -97.5% | -25.3% | 37.6% | - | -12.4% | -10.6% | -144.9% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 157.6% | -2.0% | -9.8% | -27.8% | -21.6% | 13.5% | 79.0% | 65.5% | 54.9% | -8.6% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Sierra Oncology against the 5 most active filers in the same SIC group.